News
ACAD
20.59
-0.82%
-0.17
Should Earnings Outlook Require Action From Acadia Pharmaceuticals (ACAD) Investors?
Simply Wall St · 2d ago
Tarsus Names Neera Clase Commercial Chief To Expand XDEMVY Reach And Lead Pipeline Planning
NASDAQ · 3d ago
Why Acadia Pharmaceuticals Fell Even As Profit Rose
Simply Wall St · 5d ago
Acadia Pharmaceuticals (ACAD) Stock Dropped, So What Is Driving Attention Now?
Simply Wall St · 6d ago
Weekly Report: what happened at ACAD last week (1019-1023)?
Weekly Report · 6d ago
Press Release: Acadia Pharmaceuticals to Announce Third Quarter 2026 Financial Results on November 4, 2026
Dow Jones · 10/21 20:42
Acadia Pharmaceuticals to Announce Third Quarter 2026 Financial Results on November 4, 2026
Barchart · 10/21 15:05
Analysts Offer Insights on Healthcare Companies: Recursion Pharmaceuticals (RXRX) and ACADIA Pharmaceuticals (ACAD)
TipRanks · 10/19 11:30
ACADIA Pharmaceuticals Price Target Maintained With a $35.00/Share by Needham
Dow Jones · 10/19 10:18
Needham Reiterates Buy on Acadia Pharmaceuticals, Maintains $35 Price Target
Benzinga · 10/19 10:07
Weekly Report: what happened at ACAD last week (1012-1016)?
Weekly Report · 10/19 09:27
Did Acadia Pharmaceuticals' Fall Catch You Out? What Investors Missed
Simply Wall St · 10/19 01:43
Did Raised Revenue Guidance Just Shift Acadia Pharmaceuticals (ACAD) Investment Narrative?
Simply Wall St · 10/15 18:32
Acadia Pharmaceuticals (ACAD) Could Be 42% Undervalued After Phase 2 Trial Miss
Simply Wall St · 10/14 13:22
ACADIA Pharmaceuticals Price Target Cut to $23.00/Share From $49.00 by UBS
Dow Jones · 10/13 21:00
ACADIA Pharmaceuticals Cut to Neutral From Buy by UBS
Dow Jones · 10/13 21:00
UBS Downgrades Acadia Pharmaceuticals to Neutral, Lowers Price Target to $23
Benzinga · 10/13 20:50
Acadia Pharmaceuticals downgraded to Neutral from Buy at UBS
TipRanks · 10/13 11:20
Analysts Offer Insights on Healthcare Companies: Pfizer (PFE), ACADIA Pharmaceuticals (ACAD) and Insmed (INSM)
TipRanks · 10/12 17:10
Weekly Report: what happened at ACAD last week (1005-1009)?
Weekly Report · 10/12 09:29
More
Webull provides a variety of real-time ACAD stock news. You can receive the latest news about Acadia Pharmaceuticals Inc through multiple platforms. This information may help you make smarter investment decisions.
About ACAD
Acadia Pharmaceuticals Inc.is a biopharmaceutical company. The Company is focused on innovation that makes the difference for underserved neurological and rare disease communities around the world. Its commercial portfolio includes the first and only FDA-approved treatments for Parkinson's disease psychosis and Rett syndrome. It is also developing therapeutic advancements with diverse pipelines that include mid- to late-stage programs in Alzheimer's disease psychosis and Lewy body dementia psychosis, along with earlier-stage programs that address other underserved patient needs. Its pipeline of product candidates includes Remlifanserin (formerly ACP-204), ACP-211, ACP-711, ACP-271, ACP-259, and Antisense Oligonucleotide (ASO) Program. NUPLAZID is a selective serotonin inverse agonist/antagonist preferentially targeting the 5-HT2A receptor. NUPLAZID is developed for the treatment for Parkinson's Disease Psychosis. DAYBUE (trofinetide) is developed for the treatment of Rett Syndrome.